
April 14 (Reuters) - Schrodinger Inc SDGR.O:
SCHRÖDINGER’S STATEMENT REGARDING FDA PLAN TO PHASE OUT ANIMAL TESTING REQUIREMENT FOR MONOCLONAL ANTIBODIES AND OTHER DRUGS
SCHRODINGER INC - SCHRÖDINGER SUPPORTS FDA PLAN TO REDUCE ANIMAL TESTING REQUIREMENTS
SCHRODINGER INC - PREDICTIVE TOXICOLOGY SOLUTION EXPECTED TO LAUNCH IN H2 2025